pH, Osmosis, and Pressure in Colon Delivery

0:00Welcome to Creative Biolabs' podcast channel. Join us as we explore the cutting-edge science of targeted delivery systems that are revolutionizing medicine. Interested in the future of drug development? Subscribe now. Welcome back to the pharma frontier and part two of our series on colon-targeted drug delivery. I'm Alex, and I'm here again with drug delivery expert Dr. Lena Cruz. Last time, Lena, we talked about why targeting the colon is important and how scientists use the colon's unique bacterial enzymes to activate prodrugs. Today, we explore other clever strategies that rely on different features of the gut. Hi, Alex. Yes, today we move from biological triggers to more physical and chemical ones. While bacterial targeting is highly specific, other methods like pH-sensitive release offer their own advantages and challenges. Let's start with pH. We mentioned last time that the pH changes along the gastrointestinal tract.

1:01How is this used for colon delivery? The idea is to use polymeric coatings that dissolve at a specific pH. These are often called enteric coatings. For colon targeting, we need a coating that remains intact through the acidic stomach, say pH 1 to 2, and through the near-neutral small intestine, around pH 6.6 to 7.5, but then dissolves at the pH of the colon or the terminal ilium, which is the last part of the small intestine before the colon. So, you choose a polymer that dissolves at a pH of 7 or so? Exactly. Common polymers used include various grades of u-dragit. For example, u-dragit S100 dissolves at a pH of 7.0 or above. So, a tablet coated with u-dragit S100 would, in theory, pass through the stomach and small intestine intact and only begin to dissolve and release its drug once it reaches the higher pH environment of the terminal ilium or colon.

2:02That seems straightforward. Is it that simple in practice? Not always. There are complexities. First, the pH change from the end of the small intestine to the beginning of the colon isn't a sharp step. It can drop slightly. There can also be individual variation in that pH. Furthermore, the system must withstand not just pH, but also the mechanical stress and potential fluid penetration during its several-hour journey. A thick coating might solve some problems, but could rupture from stomach contractions. So, reliability can be an issue. Are there successful products using this method? Yes, definitely. Missalazine, or 5 amino-cellacillic acid, tablets coated with u-dragit L100 for inflammatory bowel disease. A centigraphy study, which is a kind of imaging, in patients, showed that more than 70 percent of these coated tablets disintegrated within about 3.2 hours after leaving the stomach, delivering the drug to the distal small intestine

3:07and proximal colon as intended. That's a good success rate. You mentioned time-dependent release alongside pH. How does time come into play? Great question. The relatively consistent transit time through the small intestine, about 3 hours, is a clock we can use. We can design systems that have a built-in lag time before they start releasing drug, regardless of pH. This is often called pulsatile or time-clock delivery. One design uses a hard gelatin capsule filled with drug pellets, sealed with a hydrogen plug. The plug swells slowly in intestinal fluids, and after a predetermined time, it gets pushed out, releasing the contents in the colon. So you combine a pH-sensitive coating with a time-delay mechanism for extra precision? Often, they are combined for more reliable targeting. You might have a pH-sensitive coating that only starts dissolving in the small intestine, and then the inner core has a time-dependent release mechanism.

4:10Another technique is to use polymers that swell significantly at alkaline pH. This swelling itself creates a lag time before drug release begins. Researchers have developed blends of polymers like you drag it with others that swell at the right pH and are also biodegradable by Kalonic flora for a double assurance. That's ingenious. Let's move on to osmotic release. How does that work for the colon? Osmotic delivery is a powerful controlled release technology. Imagine a tablet with a semi-permeable membrane coating. Water from the gut can slowly seep through this membrane into the tablet core. Inside the core, along with the drug, are osmotic agents, usually salts, that draw in even more water. This creates increasing hydrostatic pressure inside the tablet until it forces the dissolved drug out through a tiny laser drilled hole in the coating. So it's like a small, constant pump driven by water absorption. Precisely.

5:11For colon targeting, the challenge is to prevent this pumping action from starting too early. So, these colon-targeted osmotic systems, sometimes called OOROS cologne targeting or OOROS CT systems, have an additional enteric coating. This outer coating prevents water entry in the stomach and small intestine. Only when this enteric coating dissolves at the Kalonic pH does the osmotic pump mechanism become active. So it's a two-layer system, an outer pH sensitive coat and an inner osmotic pump core. Yes. Researchers have also combined osmotic release with microbial triggers. One study reported a microbially triggered colon-targeted osmotic pump using kytosan. Kytosan forms a gel in the presence of colonic bacteria, which then modulates the water influx and drug release specifically in the colon. It seems the strategies are getting more sophisticated by combining mechanisms. Now, what about pressure control delivery? This sounds very mechanical.

6:16It is, and it directly exploits the higher viscosity and strong peristaltic waves of the colon we talked about earlier. The principle is simple, encapsulate the drug in a capsule made of a water insoluble polymer that doesn't swell, like ethylcellulose. This thin-walled capsule is strong enough to resist dissolution and the lower pressures in the stomach and small intestine. But the colon's contractions are stronger? They are, and the contents are thicker. The increased luminal pressure from Kalonic peristalsis eventually causes the capsule to rupture or disintegrate, releasing the drug. It's a delivery system activated by the squeezing force of the gut itself. Are there designs to make this rupture more predictable? Yes. One novel capsule design has a base perforated with micropoors. This allows fluid to enter slowly, causing an recipient inside to swell. The swelling creates internal pressure that eventually triggers the membrane to rupture in a more controlled manner. This combines some aspects of swelling and

7:21osmotic pressure with the final pressure-triggered rupture. How do researchers test if these pressure systems work as intended? They conduct in vitro experiments simulating different pressures and compare them to in vivo drug absorption studies. For instance, one study developed a pressure controlled system for Theophiline to manage nocturnal asthma. The fill-coated capsules were designed to resist stomach acid for two hours and a simulated small intestine buffer for three hours before being susceptible to rupture. It's fascinating how each method, pH, time, osmosis, pressure tackles the challenge from a different angle. But I'm curious, with all these existing technologies, why is there a growing interest in nanoparticles for colon targeting, which the chapter mentions next? That's the perfect lead-in to our final episode, Alex. Nanoparticles represent the next frontier because they can potentially overcome limitations of larger systems. For example, in active inflammatory

8:22bowel disease, larger drug carriers, especially those bigger than 200 micrometers, can paradoxically increase diarrhea, worsening the patient's condition and reducing drug circulation. Nanoparticles, being much smaller, avoid this issue. And their small size offers other advantages? Significantly. During inflammation, immune cells like macrophages are highly active at the site. These cells are exceptionally good at taking up very small particles like nanoparticles. So, we can design nanoparticles that accumulate precisely at the inflamed tissue in the colon, delivering a high drug dose right where it's needed while minimizing exposure elsewhere. That sounds like a game changer for conditions like colitis. Can nanoparticles use the triggers we've discussed? Absolutely. That's their versatility. You can make nanoparticles from polysaccharides that are degraded by colonic bacteria. You can design them with pH-sensitive coatings. You can even

9:26engineer them to respond to pressure changes. They are a platform technology that can incorporate any of the colon targeting principles. I'm intrigued. In our next and final episode of this series, we'll dive deep into these nanoparticle approaches and hear about some compelling research examples. I look forward to it. The work being done with nanoparticles for colon cancer and inflammatory diseases is truly remarkable and points to a more targeted future. Listeners, don't miss our conclusion to this series on the pharma frontier. We'll see you next time.